Cellular Transformation by Human Papillomaviruses: Lessons Learned by Comparing High- and Low-risk Viruses

Overview

Journal Virology

Specialty Microbiology

Date 2012 Jan 31

PMID 22284986

Citations 74

Authors

Aloysius J Klingelhutz

Ann Roman

Affiliations

Soon will be listed here.

Abstract

The oncogenic potential of papillomaviruses (PVs) has been appreciated since the 1930s yet the mechanisms of virally-mediated cellular transformation are still being revealed. Reasons for this include: a) the oncoproteins are multifunctional, b) there is an ever-growing list of cellular interacting proteins, c) more than one cellular protein may bind to a given region of the oncoprotein, and d) there is only limited information on the proteins encoded by the corresponding non-oncogenic PVs. The perspective of this review will be to contrast the activities of the viral E6 and E7 proteins encoded by the oncogenic human PVs (termed high-risk HPVs) to those encoded by their non-oncogenic counterparts (termed low-risk HPVs) in an attempt to sort out viral life cycle-related functions from oncogenic functions. The review will emphasize lessons learned from the cell culture studies of the HPVs causing mucosal/genital tract cancers.

Citing Articles

Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.

Zhou Y, Zhang T, Wang Z, Xu X Virol J. 2025; 22(1):3.

PMID: 39780219 PMC: 11707914. DOI: 10.1186/s12985-024-02604-7.

Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.

La Frazia S, Pauciullo S, Zulian V, Garbuglia A Viruses. 2025; 16(12.

PMID: 39772271 PMC: 11728759. DOI: 10.3390/v16121965.

The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?.

Palomino-Vizcaino G, Banuelos-Villegas E, Alvarez-Salas L Int J Mol Sci. 2024; 25(23.

PMID: 39684702 PMC: 11641362. DOI: 10.3390/ijms252312991.

The role of HR-HPV integration in the progression of premalignant lesions into different cancer types.

Catalan-Castorena O, Garibay-Cerdenares O, Illades-Aguiar B, Rodriguez-Ruiz H, Zubillaga-Guerrero M, Leyva-Vazquez M Heliyon. 2024; 10(15):e34999.

PMID: 39170128 PMC: 11336306. DOI: 10.1016/j.heliyon.2024.e34999.

Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer.

Mohammadi M, Saha A, Giles-Davis W, Xiang Z, Novikov M, Hasanpourghadi M Vaccines (Basel). 2024; 12(6).

PMID: 38932345 PMC: 11209626. DOI: 10.3390/vaccines12060616.

References

Jones D, Thompson D, Munger K . Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 1998; 239(1):97-107. DOI: 10.1006/viro.1997.8851. View

Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S . Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 1998; 8(12):1277-86. View

Lin Z, Yemelyanova A, Gambhira R, Jagu S, Meyers C, Kirnbauer R . Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol. 2008; 174(1):136-43. PMC: 2631326. DOI: 10.2353/ajpath.2009.080588. View

Barrow-Laing L, Chen W, Roman A . Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology. 2010; 400(2):233-9. PMC: 2861914. DOI: 10.1016/j.virol.2010.01.034. View

Gardiol D, Kuhne C, Glaunsinger B, Lee S, Javier R, Banks L . Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene. 1999; 18(40):5487-96. DOI: 10.1038/sj.onc.1202920. View

Heck D, Yee C, Howley P, Munger K . Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A. 1992; 89(10):4442-6. PMC: 49098. DOI: 10.1073/pnas.89.10.4442. View

Strati K, Pitot H, Lambert P . Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A. 2006; 103(38):14152-7. PMC: 1599927. DOI: 10.1073/pnas.0606698103. View

Uversky V, Roman A, Oldfield C, Dunker A . Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs. J Proteome Res. 2006; 5(8):1829-42. DOI: 10.1021/pr0602388. View

Thomas M, Massimi P, Jenkins J, Banks L . HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene. 1995; 10(2):261-8. View

10.

Patel D, Huang S, Baglia L, McCance D . The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999; 18(18):5061-72. PMC: 1171577. DOI: 10.1093/emboj/18.18.5061. View

11.

Gewin L, Myers H, Kiyono T, Galloway D . Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004; 18(18):2269-82. PMC: 517520. DOI: 10.1101/gad.1214704. View

12.

Arroyo M, Bagchi S, Raychaudhuri P . Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol. 1993; 13(10):6537-46. PMC: 364713. DOI: 10.1128/mcb.13.10.6537-6546.1993. View

13.

Antinore M, Birrer M, Patel D, Nader L, McCance D . The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 1996; 15(8):1950-60. PMC: 450114. View

14.

Stoppler H, Stoppler M, Johnson E, Simbulan-Rosenthal C, Smulson M, Iyer S . The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene. 1998; 17(10):1207-14. DOI: 10.1038/sj.onc.1202053. View

15.

An J, Mo D, Liu H, Veena M, Srivatsan E, Massoumi R . Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell. 2008; 14(5):394-407. PMC: 2651888. DOI: 10.1016/j.ccr.2008.10.007. View

16.

Morgan D, Pecoraro G, Rosenberg I, Defendi V . Transformation by human papillomavirus type 16 (HPV16) DNA but not HPV6b DNA is enhanced by addition of the human cytomegalovirus enhancer. Virology. 1992; 189(2):687-94. DOI: 10.1016/0042-6822(92)90592-d. View

17.

McIntyre M, Frattini M, Grossman S, Laimins L . Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol. 1993; 67(6):3142-50. PMC: 237652. DOI: 10.1128/JVI.67.6.3142-3150.1993. View

18.

Pim D, Storey A, Thomas M, Massimi P, Banks L . Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene. 1994; 9(7):1869-76. View

19.

Dreher A, Rossing M, Kaczkowski B, Andersen D, Larsen T, Christophersen M . Differential expression of cellular microRNAs in HPV 11, -16, and -45 transfected cells. Biochem Biophys Res Commun. 2011; 412(1):20-5. DOI: 10.1016/j.bbrc.2011.07.011. View

20.

Pecoraro G, Morgan D, Defendi V . Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci U S A. 1989; 86(2):563-7. PMC: 286512. DOI: 10.1073/pnas.86.2.563. View